AngioDynamics (NASDAQ:ANGO) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

AngioDynamics, Inc. (NASDAQ:ANGO) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.91 and traded as high as $13.25. AngioDynamics shares last traded at $12.87, with a volume of 228,939 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ANGO shares. Canaccord Genuity Group raised their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Trading Down 1.8%

The stock has a market capitalization of $530.24 million, a P/E ratio of -16.50 and a beta of 0.49. The business has a 50-day moving average price of $12.61 and a two-hundred day moving average price of $10.91.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The business had revenue of $75.71 million during the quarter, compared to analysts’ expectations of $72.69 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. AngioDynamics’s revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. On average, sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, SVP Lawrence T. Weiss acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The stock was acquired at an average cost of $11.81 per share, for a total transaction of $118,100.00. Following the transaction, the senior vice president directly owned 93,597 shares in the company, valued at $1,105,380.57. This represents a 11.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO James C. Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction that occurred on Thursday, October 9th. The stock was acquired at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the purchase, the chief executive officer directly owned 882,529 shares of the company’s stock, valued at $9,840,198.35. This represents a 1.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 20,890 shares of company stock valued at $239,532 over the last 90 days. Corporate insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue acquired a new stake in shares of AngioDynamics in the 3rd quarter valued at approximately $25,000. Washington Trust Advisors Inc. acquired a new position in AngioDynamics during the 3rd quarter worth approximately $27,000. State of Wyoming bought a new position in AngioDynamics in the 2nd quarter valued at approximately $31,000. Russell Investments Group Ltd. boosted its position in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 4,268 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.